Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Women: More Prone to Lower Coronary Flow Reserve

Compared to men, women have less chances of developing obstructive coronary artery disease (CAD), but this new study suggests they are more prone to have lower coronary flow reserve, which is also a risk factor.

 

Evidently, ischemic cardiomyopathy entails far more than assessing and treating plaque burden in epicardial arteries. In women, the most prevalent pathological phenotype was low coronary flow reserve in absence of OBSTRUCTIVE CAD, while in men, most of patients presenting low coronary flow reserve had multiple vessels disease. 

 

This study, simultaneously published in Circulation, assessed 329 patients (43% women) referred for a coronary angiography after positive stress test and > 40% ejection fraction.

 

Regardless of their similar age, cardiovascular medication and ischemia extension, women had lower pretest clinical risk, with lower rates of MI and burden of angiographic CAD, compared to men.

 

Moreover, women also presented less obstructive CAD and lower revascularization rate. Despite of traditional scores, women had higher risk of events at 3 years.

 

After adjusting for epicardial disease, women continued to have higher events risk than men (HR 2.05; 95% CI 1.05-4.02).

 

No doubt, we need to better understand the relationship between microvascular dysfunction and comorbidities, such as insulin resistance or cardiac failure.

 

Coronary flow reserve could be an important risk marker, not only for prospective studies assessing the role of ischemia and revascularization, but also as a target for new anti-inflammatory or hypolipidemic drugs, or neurohormone modulators.

 

Original Title: Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease.

Presenter: Taqueti VR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...